Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction

키워드

참고문헌 (99)

1. Dykstra DD, "Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients", J Urol, 139, pp.919~922 (1988)
2. Schurch B, "Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia : a prospective study in 24 spinal cord injury patients", J Urol, 155, pp.1023~1029 (1996)
3. Dykstra DD, "Treatment of detrusor-sphincter dyssynergia with botulinum A toxin : a double-blind study", Arch Phys Med Rehabil, 71, pp.24~26 (1990)
4. de Sèze M, "Botulinum a toxin and detrusor sphincter dyssynergia : a double-blind lidocaine-controlled study in 13 patients with spinal cord disease", Eur Urol, 42, pp.56~62 (2002)
5. Kuo HC, "Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction", J Urol, 170, pp.1908~1912 (2003)
6. Schurch B, "Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients : a new alternative to anticholinergic drugs? Preliminary results", J Urol, 164, pp.692~697 (2000)
7. Reitz A, "European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity", Eur Urol, 45, pp.510~515 (2004)
8. Dong M, "SV2is the protein receptor for botulinum neurotoxin A", Science, 312, pp.592~596 (2006)
9. Cruz F, "Targets for botulinum toxin in the lower urinary tract", Neurourol Urodyn, 33, pp.31~38 (2014)
10. Kanai A, "Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011", Neurourol Urodyn, 31, pp.300~308 (2012)
11. Apostolidis A, "Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity", Eur Urol, 49, pp.644~650 (2006)
12. Schulte-Baukloh H, "Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a singleblind study", Urology, 81, pp.1052~1057 (2013)
13. Smith CP, "Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation : effect of botulinum toxin A", Neurochem Int, 47, pp.291~297 (2005)
14. Smith CP, "Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury", Neurochem Int, 52, pp.1068~1075 (2008)
15. Yiangou Y, "Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder", BJU Int, 87, pp.774~779 (2001)
16. Schurch B, "Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study", J Urol, 174, pp.196~200 (2005)
17. Phelan MW, "Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction", J Urol, 165, pp.1107~1110 (2001)
18. Mehta S, "A metaanalysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury", Arch Phys Med Rehabil, 93, pp.597~603 (2012)
19. Kuo HC, "Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion", Neurourol Urodyn, 27, pp.793~796 (2008)
20. Smith CP, "Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra", Urology, 65, pp.37~41 (2005)
21. Gallien P, "Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients", J Neurol Neurosurg Psychiatry, 76, pp.1670~1676 (2005)
22. Mahfouz W, "Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update", Can J Urol, 18, pp.5787~5795 (2011)
23. Kuo HC, "Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia", Int J Clin Pract, 67, pp.1044~1049 (2013)
24. Chen YH, "Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions", Urol Int, 73, pp.156~161 (2004)
25. Vallès M, "Cerebral hemorrhage due to autonomic dysreflexia in a spinal cord injury patient", Spinal Cord, 43, pp.738~740 (2005)
26. Karlsson AK, "Autonomic dysreflexia", Spinal Cord, 37, pp.383~391 (1999)
27. Tsai SJ, "Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia : localization with combined fluoroscopic and electromyographic guidance", Arch Phys Med Rehabil, 90, pp.832~836 (2009)
28. Michel F, "Botulinum toxin type A injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity:preliminary results of a salvage strategy. The ENTEROTOX Study", Urology, 129, pp.43~47 (2019)
29. Tow AM, "Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore", Ann Acad Med Singapore, 36, pp.11~17 (2007)
30. Chen SF, "Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity", J Formos Med Assoc, 114, pp.583~589 (2015)
31. Ehren I, "Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study", Scand J Urol Nephrol, 41, pp.335~340 (2007)
32. Patki PS, "Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury", BJU Int, 98, pp.77~82 (2006)
33. Anquetil C, "Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty : impact on the quality of life of patients with SCI", Spinal Cord, 54, pp.1031~1035 (2016)
34. Kennelly M, "Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity : an interim analysis", Urology, 81, pp.491~497 (2013)
35. Rovner E, "OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity", Neurourol Urodyn, 32, pp.1109~1115 (2013)
36. Apostolidis A, "An exploratory, placebo-controlled, dose–response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity", World J Urol, 31, pp.1469~1474 (2013)
37. Giannantoni A, "Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity : clinical and urodynamic results", Eur Urol, 55, pp.705~711 (2009)
38. Kalsi V, "Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes", Eur Urol, 49, pp.528~535 (2006)
39. Cruz F, "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial", Eur Urol, 60, pp.742~750 (2011)
40. Akbar M, "Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction", BJU Int, 100, pp.639~645 (2007)
41. Mangera A, "An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders", Eur Urol, 65, pp.981~990 (2014)
42. Schurch B, "Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence", Eur Urol, 52, pp.850~858 (2007)
43. Gamé X, "Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections", Eur Urol, 53, pp.613~618 (2008)
44. MacDonald R, "Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity : a systematic review of effectiveness and adverse effects", Spinal Cord, 45, pp.535~541 (2007)
45. Mouttalib S, "Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment", BJU Int, 106, pp.1677~1680 (2010)
46. Chen CY, "Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia", Spinal Cord, 49, pp.659~664 (2011)
47. regardless of concomitant anticholinergic use or neurologic etiology, "Adv Ther", 2013, 819~833
48. Hori S, "Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury", BJU Int, 104, pp.216~220 (2009)
49. Chancellor MB, "OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity", Neurology, 81, pp.841~848 (2013)
50. Mangera A, "Contemporary management of lower urinary tract disease with botulinum toxin A : a systematic review of Botox(onabotulinumtoxinA)and Dysport(abobotulinumtoxinA)", Eur Urol, 60, pp.784~795 (2011)
51. Kuo HC, "Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents", Urology, 63, pp.868~872 (2004)
52. Ginsberg D, "Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity", J Urol, 187, pp.2131~2139 (2012)
53. Herschorn S, "Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial", J Urol, 185, pp.2229~2235 (2011)
54. Sussman D, "Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity", Neurourol Urodyn, 32, pp.242~249 (2013)
55. Chen YC, "The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients", Neurourol Urodyn, 33, pp.129~134 (2014)
56. Kuo HC, "Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection", Urology, 72, pp.1056~1060 (2008)
57. McKenzie P, "The incidence and etiology of overactive bladder in patients after cerebrovascular accident", Curr Urol Rep, 13, pp.402~406 (2012)
58. Ruffion A, "Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder", Neuroepidemiology, 41, pp.146~155 (2013)
59. Schulte-Baukloh H, "Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients : an objective and subjective analysis", Neurourol Urodyn, 25, pp.110~115 (2006)
60. Khan S, "Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis", J Urol, 185, pp.1344~1349 (2011)
61. Gaillet S, "Five years follow-up study and failures analysis of botulinum toxin repeated injections to treat neurogenic detrusor overactivity", Prog Urol, 22, pp.1064~1070 (2012)
62. Mehnert U, "The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis : a pilot study", J Urol, 184, pp.1011~1016 (2010)
63. Kulaksizoglu H, "Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease", Parkinsonism Relat Disord, 16, pp.531~534 (2010)
64. Giannantoni A, "Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder", J Urol, 186, pp.960~964 (2011)
65. Giannantoni A, "Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy", J Urol, 182, pp.1453~1457 (2009)
66. Anderson RU, "OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson’s disease", Urology, 83, pp.22~27 (2014)
67. Kuo HC, "Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions", Urology, 67, pp.232~236 (2006)
68. Jiang YH, "Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder", PLoS One, 9, pp.e105989~ (2014)
69. Dmochowski R, "Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial", J Urol, 184, pp.2416~2422 (2010)
70. Liao CH, "Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity", J Urol, 189, pp.1804~1810 (2013)
71. Schurch B, "OnabotulinumtoxinA and multiple sclerosis", Ann Phys Rehabil Med, 57, pp.302~314 (2014)
72. Apostolidis A, "Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions : a European consensus report", Eur Urol, 55, pp.100~119 (2009)
73. Schulte-Baukloh H, "Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele : preliminary results", Urology, 59, pp.325~327 (2002)
74. Riccabona M, "Botulinum-A toxin injection into the detrusor : a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia", J Urol, 171, pp.845~848 (2004)
75. Altaweel W, "Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele", J Urol, 175, pp.1102~1105 (2006)
76. Kajbafzadeh AM, "Intravesical injection of botulinum toxin type A : management of neuropathic bladder and bowel dysfunction in children with myelomeningocele", Urology, 68, pp.1091~1096 (2006)
77. Horst M, "Repeated botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele", Neurourol Urodyn, 30, pp.1546~1549 (2011)
78. Safari S, "Intravesical injections of botulinum toxin type A for management of neuropathic bladder : a comparison of two methods", Urology, 76, pp.225~230 (2010)
79. Kuo HC, "Investigation of dysfunctional voiding in children with urgency frequency syndrome and urinary incontinence", Urol Int, 76, pp.72~76 (2006)
80. Radojicic ZI, "Is it reasonable to treat refractory voiding dysfunction in children with botulinum-A toxin", J Urol, 176, pp.332~336 (2006)
81. Mokhless I, "Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder", J Urol, 176, pp.1767~1770 (2006)
82. Vricella GJ, "Longterm efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children", J Urol, 191, pp.1586~1591 (2014)
83. Lahdes-Vasama TT, "Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence : a pilot study", Scand J Urol Nephrol, 45, pp.397~400 (2011)
84. McDowell DT, "Urinary incontinence in children : botulinum toxin is a safe and effective treatment option", Pediatr Surg Int, 28, pp.315~320 (2012)
85. Marte A, "Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children", Eur J Pediatr Surg, 20, pp.153~157 (2010)
86. El-Masri WS, "Long-term followup study of outcomes of bladder management in spinal cord injury patients under the care of the Midlands Centre for spinal injury in Oswestry", Spinal Cord, 50, pp.14~21 (2012)
87. Kuo HC, "Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries", Neurourol Urodyn, 30, pp.1541~1545 (2011)
88. Jacobson AF, "Relation of changes in radionuclide measures of effective renal plasma flow and glomerular filtration rate in spinal cord injury patients", J Am Paraplegia Soc, 17, pp.15~19 (1994)
89. Just A, "Role of angiotensin II in dynamic renal blood flow autoregulation of the conscious dog", J Physiol, 538, pp.167~177 (2002)
90. Cameron AP, "Systematic review of urological followup after spinal cord injury", J Urol, 187, pp.391~397 (2012)
91. Krebs J, "Real-world effects of mirabegron in patients with chronic neurogenic detrusor overactivity-a retrospective cohort study", Res Rep Urol, 12, pp.187~192 (2020)
92. Chen JL, "Long-term outcomes of augmentation enterocystoplasty with an ileal segment in patients with spinal cord injury", J Formos Med Assoc, 108, pp.475~480 (2009)
93. Krebs J, "Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction", Neurourol Urodyn, 35, pp.260~266 (2016)
94. Lendvay TS, "Augmentation cystoplasty rates at children’s hospitals in the United States : a Pediatric Health Information System database study", J Urol, 176, pp.1716~1720 (2006)
95. Reyblat P, "Augmentation cystoplasty : what are the indications", Curr Urol Rep, 9, pp.452~458 (2008)
96. Ku JH, "The management of neurogenic bladder and quality of life in spinal cord injury", BJU Int, 98, pp.739~745 (2006)
97. Wu SY, "A real-world experience with augmentation enterocystoplasty-High patient satisfaction with high complication rates", Neurourol Urodyn, 37, pp.744~750 (2018)
98. Weld KJ, "Association of Level of injury and bladder behavior in patients with post-traumatic spinal cord injury", Urology, 55, pp.490~494 (2000)
99. Schulte-Baukloh H, "Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome : objective outcome and patient satisfaction", Eur Urol, 48, pp.984~990 (2005)

관련 논문AI추천